Literature DB >> 28083624

[Perioperative management of patients on NOACs].

C Kelm1, K Engels2.   

Abstract

Regarding thromboembolic events, non-vitamin K antagonists, so-called new oral anticoagulative agents (NOACs), have widely enlarged prophylaxis and therapy. In contrast to vitamin K antagonists they can be administered in a definite dose and do not need any regular control of coagulation parameters. Thus being simple in handling, these drugs have become enormously attractive for both patient and physician.In spite of all their advantages NOACs have to be considered carefully. They have a significant disadvantage: the plasma concentration is not detectable by a simple blood test, nor is there any antidote available. As a consequence the bleeding risk remains unknown.In this review we focus on two different settings in routine surgical work: the preoperative management of patients undergoing elective surgery differs significantly from that needed in urgent surgery.

Entities:  

Keywords:  Emergencies; Hemorrhage; Prophylaxis; Surgery; Thromboembolism

Mesh:

Substances:

Year:  2017        PMID: 28083624     DOI: 10.1007/s00063-016-0244-y

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  18 in total

1.  Antidote for Factor Xa Anticoagulants.

Authors:  Jean M Connors
Journal:  N Engl J Med       Date:  2015-11-11       Impact factor: 91.245

2.  Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.

Authors:  Jan Beyer-Westendorf; Kati Förster; Sven Pannach; Franziska Ebertz; Vera Gelbricht; Christoph Thieme; Franziska Michalski; Christina Köhler; Sebastian Werth; Kurtulus Sahin; Luise Tittl; Ulrike Hänsel; Norbert Weiss
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

3.  Targeted Anti-Anticoagulants.

Authors:  Kenneth A Bauer
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

4.  A randomised controlled pilot trial to evaluate and optimize the use of anti-platelet agents in the perioperative management in patients undergoing general and abdominal surgery--the APAP trial (ISRCTN45810007).

Authors:  D Antolovic; A Rakow; P Contin; A Ulrich; N N Rahbari; M W Büchler; J Weitz; M Koch
Journal:  Langenbecks Arch Surg       Date:  2011-11-03       Impact factor: 3.445

5.  Perioperative Management of Dabigatran: A Prospective Cohort Study.

Authors:  Sam Schulman; Marc Carrier; Agnes Y Y Lee; Sudeep Shivakumar; Mark Blostein; Frederick A Spencer; Susan Solymoss; Rebecca Barty; Grace Wang; Nancy Heddle; James D Douketis
Journal:  Circulation       Date:  2015-05-12       Impact factor: 29.690

6.  Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

Authors:  David J Graham; Marsha E Reichman; Michael Wernecke; Rongmei Zhang; Mary Ross Southworth; Mark Levenson; Ting-Chang Sheu; Katrina Mott; Margie R Goulding; Monika Houstoun; Thomas E MaCurdy; Chris Worrall; Jeffrey A Kelman
Journal:  Circulation       Date:  2014-10-30       Impact factor: 29.690

7.  Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.

Authors:  Bram J Geller; Robert P Giugliano; Eugene Braunwald; Sabina A Murphy; James J Hanyok; Jianqing Jin; Michele Mercuri; Elliott M Antman; Christian T Ruff
Journal:  Am Heart J       Date:  2015-07-02       Impact factor: 4.749

8.  [Treatment safety of non-vitamin K oral anticoagulants in patients with atrial fibrillation].

Authors:  S H Hohnloser
Journal:  Herz       Date:  2016-02       Impact factor: 1.443

9.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

10.  Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban.

Authors:  Sally Tamayo; W Frank Peacock; Manesh Patel; Nicholas Sicignano; Kathleen P Hopf; Larry E Fields; Troy Sarich; Shujian Wu; Daniel Yannicelli; Zhong Yuan
Journal:  Clin Cardiol       Date:  2015-01-14       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.